Alverno Laboratories, LLC

Alverno Laboratories, LLC was paid $33.87M by Medicaid between Jan 2018 and Dec 2024, across 241 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 6.9% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Indiana

Rank by total paid#1 of 66

Median peer was paid$53K

This provider vs. median644×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	262,300	$2.07M
2019	301,869	$4.14M
2020	310,248	$4.21M
2021	413,588	$6.40M
2022	507,520	$6.90M
2023	480,681	$6.00M
2024incomplete	348,878	$4.15M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	6.9%	34,285	29,211	$2.32M
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	6.0%	59,234	52,496	$2.03M
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	5.9%	58,606	52,696	$2.01M
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	5.8%	36,893	32,671	$1.97M
84443	Thyroid stimulating hormone (TSH)	5.3%	140,776	125,381	$1.79M
80053	Comprehensive metabolic panel	4.8%	214,797	187,431	$1.63M
80050	General health panel	4.3%	33,033	30,846	$1.44M
80061	Lipid panel	3.3%	179,315	157,306	$1.11M
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	3.3%	84,132	73,040	$1.11M
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	3.1%	24,046	19,997	$1.05M
85025	Blood count; complete (CBC), automated, and automated differential WBC count	3.0%	216,833	187,916	$1.02M
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	2.7%	22,913	18,598	$917K

229 more codes

88175	Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer	2.7%	51,936	$900K
87624	Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types	2.2%	28,783	$732K
83036	Hemoglobin; glycosylated (A1C)	1.8%	111,658	$623K
87086	Culture, bacterial; quantitative colony count, urine	1.6%	79,660	$542K
87637	Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV	1.6%	6,018	$541K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	1.6%	24,469	$539K
36415	Collection of venous blood by venipuncture	1.4%	153,335	$466K
82607		1.3%	45,529	$449K
87480		1.3%	24,027	$437K
87510		1.3%	23,986	$436K
86235		1.1%	3,871	$374K
87660		1.1%	24,400	$369K
80081		1.1%	6,593	$366K
86780		1.0%	25,770	$347K
84439		<1%	46,791	$316K
88305	Level IV - Surgical pathology, gross and microscopic examination	<1%	10,470	$307K
86480		<1%	6,822	$300K
86803		<1%	21,441	$283K
86003		<1%	6,771	$278K
87481		<1%	6,537	$261K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	<1%	925	$254K
87186		<1%	28,955	$237K
80074		<1%	7,133	$227K
81514		<1%	2,405	$220K
82728		<1%	26,540	$201K
84153		<1%	14,405	$171K
80048	Basic metabolic panel (calcium, ionized)	<1%	30,434	$157K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	5,269	$146K
82570		<1%	39,625	$143K
87081		<1%	26,274	$134K
87536		<1%	2,182	$133K
87070		<1%	21,910	$125K
83550		<1%	19,461	$122K
81001		<1%	55,151	$122K
83970		<1%	5,166	$120K
82043		<1%	34,442	$119K
83540		<1%	25,288	$119K
84403		<1%	5,528	$112K
86481		<1%	2,165	$109K
82746		<1%	10,945	$103K
83001		<1%	6,630	$100K
87340		<1%	9,863	$96K
87522	Neg quan hep c or qual rna	<1%	2,600	$94K
84702		<1%	10,438	$88K
87077		<1%	14,749	$79K
84481		<1%	8,106	$78K
85027		<1%	16,752	$76K
85651		<1%	23,949	$75K
83735		<1%	17,288	$73K
86038		<1%	6,352	$72K
86696		<1%	4,152	$66K
83655		<1%	6,648	$66K
84146		<1%	5,197	$65K
86140		<1%	17,559	$61K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	1,047	$61K
88342		<1%	1,771	$60K
87088		<1%	8,248	$57K
G0103	Prostate cancer screening; prostate specific antigen test (psa)	<1%	5,437	$57K
86769		<1%	1,565	$56K
86695		<1%	4,415	$51K
84550		<1%	15,446	$50K
86706		<1%	4,798	$49K
86360		<1%	1,613	$49K
86376		<1%	5,334	$48K
86787		<1%	3,753	$46K
83002		<1%	4,641	$45K
83880		<1%	2,627	$45K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	1,105	$44K
86225		<1%	4,571	$44K
82785		<1%	4,865	$40K
86431		<1%	7,670	$39K
86359		<1%	1,623	$37K
82670		<1%	2,532	$36K
84270		<1%	2,303	$36K
80076		<1%	6,351	$36K
86762		<1%	4,186	$35K
86800		<1%	3,224	$34K
87529		<1%	772	$34K
87581		<1%	993	$34K
87486		<1%	988	$34K
81003		<1%	19,599	$33K
84144		<1%	2,607	$32K
87636	Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B	<1%	282	$32K
82784		<1%	3,699	$31K
86200		<1%	3,432	$31K
82950		<1%	7,768	$30K
83690		<1%	5,789	$29K
83013		<1%	897	$29K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	1,377	$28K
85610		<1%	9,563	$27K
82627		<1%	2,272	$26K
86160		<1%	1,949	$26K
82550		<1%	6,406	$25K
81220	CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants	<1%	541	$25K
82533		<1%	2,205	$24K
84480		<1%	2,657	$22K
87205		<1%	7,620	$22K
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	<1%	331	$21K
82951		<1%	1,964	$21K
86704		<1%	1,781	$21K
86735		<1%	1,731	$19K
88312		<1%	366	$19K
86850		<1%	3,337	$19K
87631		<1%	254	$18K
86141		<1%	1,366	$18K
82105		<1%	1,330	$18K
83516		<1%	1,890	$17K
84436		<1%	3,301	$16K
84466		<1%	1,845	$16K
85730		<1%	3,574	$16K
87493		<1%	482	$14K
86765		<1%	1,826	$14K
82274		<1%	1,442	$14K
84681		<1%	983	$14K
83721		<1%	2,648	$14K
86364		<1%	1,945	$13K
84100		<1%	4,764	$13K
84156		<1%	5,800	$13K
84703		<1%	2,020	$13K
83020		<1%	1,458	$13K
80069		<1%	2,823	$12K
87653		<1%	366	$12K
87804	Infectious agent antigen detection by immunoassay; Influenza, each type	<1%	421	$12K
87338		<1%	830	$12K
86039		<1%	1,326	$12K
86901		<1%	3,515	$11K
82652		<1%	746	$11K
83525		<1%	1,187	$11K
86336		<1%	572	$10K
82150		<1%	2,155	$10K
86694		<1%	900	$10K
86592		<1%	3,010	$10K
86255		<1%	1,481	$10K
87328		<1%	852	$10K
84460		<1%	2,955	$9K
87045		<1%	1,125	$9K
86618		<1%	675	$9K
85379		<1%	1,289	$9K
88341		<1%	133	$8K
86900		<1%	3,113	$8K
80164		<1%	1,543	$8K
86677		<1%	853	$8K
83615		<1%	1,941	$8K
84165		<1%	1,181	$8K
82677		<1%	562	$7K
87210		<1%	1,784	$7K
83520		<1%	660	$7K
86334		<1%	502	$7K
87147		<1%	2,037	$7K
87329		<1%	831	$7K
85007		<1%	2,359	$6K
87046		<1%	1,150	$6K
86147		<1%	227	$6K
80177		<1%	740	$6K
87075		<1%	858	$5K
84134		<1%	500	$5K
82947		<1%	1,795	$5K
84432		<1%	376	$5K
88304		<1%	224	$5K
82952		<1%	1,346	$4K
80055		<1%	99	$4K
85044		<1%	1,457	$4K
82248		<1%	1,313	$4K
87641		<1%	124	$4K
86812		<1%	256	$4K
U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc	<1%	97	$4K
86708		<1%	405	$3K
82977		<1%	766	$3K
86231		<1%	432	$3K
82378		<1%	361	$3K
82747		<1%	258	$3K
80178		<1%	699	$3K
82330		<1%	305	$3K
84450		<1%	796	$3K
84484		<1%	290	$3K
82565		<1%	814	$3K
P9604	Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge	<1%	1,697	$2K
86304		<1%	149	$2K
82140		<1%	258	$2K
85520		<1%	250	$2K
88112		<1%	101	$2K
83993		<1%	183	$2K
86060		<1%	331	$2K
81025		<1%	287	$2K
85660		<1%	401	$2K
G0475	Hiv antigen/antibody, combination assay, screening	<1%	270	$2K
G0145	Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision	<1%	1,358	$1K
84154		<1%	116	$1K
86593		<1%	390	$1K
86256		<1%	96	$1K
85613		<1%	174	$1K
84155		<1%	589	$1K
82465		<1%	361	$1K
85670		<1%	246	$1K
86146		<1%	31	$1K
G0472	Hepatitis c antibody screening, for individual at high risk and other covered indication(s)	<1%	753	$1K
85732		<1%	159	$975.79
86665		<1%	41	$917.28
84132		<1%	260	$839.56
82310		<1%	173	$633.51
80349		<1%	41	$607.16
86705		<1%	48	$548.84
86308		<1%	143	$535.07
86300		<1%	27	$413.82
84520		<1%	133	$385.65
87076		<1%	60	$385.58
86880		<1%	88	$363.43
82040		<1%	110	$343.41
86015		<1%	45	$302.73
84479		<1%	93	$300.72
84425		<1%	42	$289.37
87106		<1%	39	$281.92
83090		<1%	24	$277.46
82085		<1%	39	$227.92
86361		<1%	13	$203.01
86778		<1%	13	$170.61
87420		<1%	12	$159.94
87206		<1%	53	$153.41
87324		<1%	15	$150.79
G0499	Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result	<1%	12	$140.78
82390		<1%	18	$134.06
87185		<1%	33	$111.55
87800		<1%	12	$87.25
82340		<1%	16	$73.76
0753T		<1%	388	$68.70
85014		<1%	88	$56.09
82247		<1%	59	$51.54
G0476	Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test	<1%	55	$6.88
0760T		<1%	81	$4.80

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialTERESE, SAM (CEO AND PRESIDENT)